Lipid-lowering injections are currently targeted at people who need to reduce the risk of cardiovascular disease and familial hyperlipidemia. There are two commonly used lipid-lowering injections, iloyumab injection and aliskirenumab injection, to reduce the risk of myocardial infarction, unstable angina pectoris, stroke, and coronary revascularization, and to treat adults with primary hypercholesterolemia and mixed dyslipidemia. Patients at high risk for cardiovascular disease, such as those who have had both a myocardial infarction and a cerebral infarction within one year, should have their LDL cholesterol rapidly reduced to 1.4 mmol/L or 1.0 mmol/L or less, and need to be treated with one of the above lipid-lowering injections. Adults with primary hypercholesterolemia applying the above two lipid-lowering injections are more effective. The main adverse effects of alloxizumab injection include upper respiratory tract infections, gastroenteritis and nasopharyngitis, and it is contraindicated for those who are allergic to its ingredients. The main adverse effects of aliskirenumab injection include local injection reactions and allergic reactions, and it is contraindicated for those who are allergic to its ingredients. The above two drugs are western prescription drugs, should be under the professional guidance of specialized physicians to choose drugs and dosage, avoid self-purchase and self-medication, the use of the process of strict monitoring of adverse drug reactions.